Literature DB >> 32636113

Validation of a new prognostic body composition parameter in cancer patients.

Emanuele Cereda1, Marilisa Caraccia2, Catherine Klersy3, Silvia Cappello2, Annalisa Turri2, Valeria Borioli2, Nicole Stobäus4, Antonello Giannoni5, Luca Arcaini6, Marco Benazzo7, Giovanni Palladini8, Paolo Pedrazzoli9, Kristina Norman10, Riccardo Caccialanza2.   

Abstract

BACKGROUND & AIMS: Estimation errors associated with bioelectric impedance evaluation may affect the accuracy of body composition and its prognostic value. We evaluated the prognostic value of a new body composition parameter (Nutrigram®) obtained from bioimpedance vectorial analysis-derived body cell mass and its association with nutritional and functional status.
DESIGN: Data of Italian and German cancer patients observed prospectively until death were used. Multivariable models (adjusted for age, gender, hydration status, performance status, and disease's stage) were built in both cohorts to assess the association between body composition outcome parameters (low fat-free mass [FFM], <15 [females] and <17 [males] kg/m2; low standardized phase angle [SPA], <-1.65; low Nutrigram®, <510 [females] and <660 [males] mg/24 h/m) and 1-year all-cause mortality, low body mass index (BMI; <20 [<70 years] and <22 [≥70 years] kg/m2), clinically significant weight loss (WL; ≥10% in 6 months) and low handgrip strength (HG; <20 [females] and <30 [males] kg).
RESULTS: Low Nutrigram® was independently associated with mortality in both Italian (HR = 1.84 [95%CI, 1.18-2.86]; P = 0.007) and German cohorts (HR = 1.52 [95%CI, 1.17-2.07]; P = 0.008). Low FFMI and low SPA did not predict survival in the German cohort. In patients with low Nutrigram®, worse nutritional and functional status were observed in both study populations. Performance of models addressing the study endpoints showed substantial consistency with both cohorts, particularly of those including low Nutrigram®.
CONCLUSIONS: We validated a new prognostic body composition parameter, which is easier to interpret than standard nutritional parameters and may be useful for identifying cancer patients at nutritional risk, requiring early nutritional support.
Copyright © 2020 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Keywords:  Body composition; Cancer patients; Fat-free mass index; Mortality; Phase angle

Year:  2020        PMID: 32636113     DOI: 10.1016/j.clnu.2020.06.011

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  3 in total

1.  Phase Angle Is a Stronger Predictor of Hospital Outcome than Subjective Global Assessment-Results from the Prospective Dessau Hospital Malnutrition Study.

Authors:  Mathias Plauth; Isabella Sulz; Melanie Viertel; Veronika Höfer; Mila Witt; Frank Raddatz; Michael Reich; Michael Hiesmayr; Peter Bauer
Journal:  Nutrients       Date:  2022-04-24       Impact factor: 6.706

2.  Muscle weakness as an additional criterion for grading sarcopenia-related prognosis in patients with cancer.

Authors:  Emanuele Cereda; Richard Tancredi; Catherine Klersy; Federica Lobascio; Silvia Crotti; Sara Masi; Silvia Cappello; Nicole Stobäus; Maja Tank; Sara Cutti; Luca Arcaini; Elisabetta Bonzano; Sara Colombo; Paolo Pedrazzoli; Kristina Norman; Riccardo Caccialanza
Journal:  Cancer Med       Date:  2021-12-10       Impact factor: 4.452

3.  The efficacy of immunonutrition in improving tolerance to chemoradiotherapy in patients with head and neck cancer, receiving nutritional counseling: study protocol of a randomized, open-label, parallel group, bicentric pilot study.

Authors:  Riccardo Caccialanza; Emanuele Cereda; Catherine Klersy; Mariateresa Nardi; Sara Masi; Silvia Crotti; Silvia Cappello; Valentina Caissutti; Carlotta Brovia; Federica Lobascio; Elena Formisano; Sara Colombo; Andrea Riccardo Filippi; Elisabetta Bonzano; Patrizia Comoli; Laura Catenacci; Andrea Alberti; Valeria Musella; Alessandra Ferrari; Ilaria Imarisio; Richard Tancredi; Teresa Monaco; Maria Grazia Ghi; Paolo Bossi; Paolo Pedrazzoli
Journal:  Ther Adv Med Oncol       Date:  2021-09-11       Impact factor: 8.168

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.